• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Renal Failure in Sickle Cell Disease: Prevalence, Predictors of Disease, Mortality and Effect on Length of Hospital Stay.镰状细胞病中的肾衰竭:患病率、疾病预测因素、死亡率及对住院时间的影响
Hemoglobin. 2016 Sep;40(5):295-299. doi: 10.1080/03630269.2016.1224766. Epub 2016 Sep 18.
2
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.小儿镰状细胞血管阻塞性疼痛危象期间的急性肾损伤
Pediatr Nephrol. 2017 Aug;32(8):1451-1456. doi: 10.1007/s00467-017-3623-6. Epub 2017 Feb 25.
3
Prevalence, treatment, and outcomes of renal conditions in pediatric sickle cell disease.小儿镰状细胞病肾脏疾病的患病率、治疗及转归
South Med J. 2011 Nov;104(11):752-6. doi: 10.1097/SMJ.0b013e318232d9ab.
4
Prevalence, Mortality, and Access to Care for Chronic Kidney Disease in Medicaid-Enrolled Adults With Sickle Cell Disease in California: Retrospective Cohort Study.加利福尼亚州参加医疗补助计划的镰状细胞病成年患者中慢性肾脏病的患病率、死亡率和获得治疗的情况:回顾性队列研究。
JMIR Public Health Surveill. 2024 Jul 15;10:e57290. doi: 10.2196/57290.
5
Chronic kidney disease is common in sickle cell disease: a cross-sectional study in the Tema Metropolis, Ghana.慢性肾脏病在镰状细胞病中很常见:加纳特马市的一项横断面研究。
BMC Nephrol. 2015 May 29;16:75. doi: 10.1186/s12882-015-0072-y.
6
Renal Failure After Cardiac Operations: Not All Acute Kidney Injury Is the Same.心脏手术后的肾衰竭:并非所有急性肾损伤都相同。
Ann Thorac Surg. 2017 Sep;104(3):760-766. doi: 10.1016/j.athoracsur.2017.01.019. Epub 2017 Apr 21.
7
The significance of reduced kidney function among hospitalized acute general medical patients.住院急性综合医学患者肾功能降低的意义。
QJM. 2013 Jan;106(1):59-65. doi: 10.1093/qjmed/hcs192. Epub 2012 Oct 15.
8
Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.镰状细胞病中的慢性肾衰竭:危险因素、临床病程及死亡率
Ann Intern Med. 1991 Oct 15;115(8):614-20. doi: 10.7326/0003-4819-115-8-614.
9
Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure.因失代偿性充血性心力衰竭住院患者发生急性肾衰竭的风险。
Am J Nephrol. 2007;27(1):55-62. doi: 10.1159/000099012. Epub 2007 Jan 24.
10
Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis.镰状细胞病危象住院成年患者的输血与30天再入院率
Transfusion. 2015 Oct;55(10):2331-8. doi: 10.1111/trf.13155. Epub 2015 Jun 30.

引用本文的文献

1
Kidney function after nonmyeloablative hematopoietic cell transplant for sickle cell disease.镰状细胞病非清髓性造血细胞移植后的肾功能
Bone Marrow Transplant. 2025 May;60(5):690-696. doi: 10.1038/s41409-025-02550-0. Epub 2025 Mar 22.
2
Nitrated fatty acids protect against acute kidney injury in sickle cell disease.硝化脂肪酸可预防镰状细胞病中的急性肾损伤。
Blood Adv. 2025 Jun 24;9(12):2886-2890. doi: 10.1182/bloodadvances.2024015038.
3
Factors Associated with Microalbuminuria among Children with Sickle Cell Disease in a Tertiary Centre in South-South Nigeria.尼日利亚南南地区一家三级中心镰状细胞病患儿微量白蛋白尿的相关因素
Niger Med J. 2025 Jan 10;65(6):885-898. doi: 10.60787/nmj-v65i6.493. eCollection 2024 Nov-Dec.
4
Effects of GBT1118, a voxelotor analog, on bone disease in sickle cell disease mice.GBT1118(一种 voxelotor 类似物)对镰状细胞病小鼠骨病的影响。
Sci Rep. 2024 Sep 27;14(1):22330. doi: 10.1038/s41598-024-69589-9.
5
End Organ Affection in Sickle Cell Disease.镰状细胞病的靶器官损害。
Cells. 2024 May 29;13(11):934. doi: 10.3390/cells13110934.
6
Fibroblast Growth Factor 23 Neutralizing Antibody Ameliorates Abnormal Renal Phosphate Handling in Sickle Cell Disease Mice.成纤维细胞生长因子 23 中和抗体可改善镰状细胞病小鼠的肾脏磷酸盐异常处理。
Endocrinology. 2023 Nov 2;164(12). doi: 10.1210/endocr/bqad173.
7
Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease.机器学习预测住院镰状细胞病患者的急性肾损伤。
Am J Nephrol. 2024;55(1):18-24. doi: 10.1159/000534864. Epub 2023 Oct 31.
8
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease.镰状细胞病患者的血红蛋白与终末器官损伤
Curr Ther Res Clin Exp. 2023 Feb 23;98:100696. doi: 10.1016/j.curtheres.2023.100696. eCollection 2023.
9
Acute kidney injury in Jamaicans with sickle cell disease hospitalized with COVID-19 infection.因新型冠状病毒肺炎感染住院的镰状细胞病牙买加患者的急性肾损伤
EJHaem. 2023 Jan 7;4(1):37-44. doi: 10.1002/jha2.636. eCollection 2023 Feb.
10
Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease.病例报告:伐昔洛韦对一名镰状细胞病合并IV期慢性肾脏病患者的安全性和有效性
Front Med (Lausanne). 2022 Sep 15;9:931924. doi: 10.3389/fmed.2022.931924. eCollection 2022.

本文引用的文献

1
Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.成人镰状细胞病中的迟发性溶血性输血反应:99 例转诊中心病例的表现、结局和治疗。
Am J Hematol. 2016 Oct;91(10):989-94. doi: 10.1002/ajh.24460. Epub 2016 Jul 14.
2
Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.镰状细胞贫血慢性输血患儿的器官铁蓄积:TWiTCH试验的基线结果
Br J Haematol. 2016 Jan;172(1):122-30. doi: 10.1111/bjh.13791. Epub 2015 Nov 2.
3
Blood transfusion and 30-day readmission rate in adult patients hospitalized with sickle cell disease crisis.镰状细胞病危象住院成年患者的输血与30天再入院率
Transfusion. 2015 Oct;55(10):2331-8. doi: 10.1111/trf.13155. Epub 2015 Jun 30.
4
Clinical Factors Associated with Morbidity and Mortality in Patients Admitted with Sickle Cell Disease.镰状细胞病入院患者发病和死亡的相关临床因素
West Indian Med J. 2014 Dec;63(7):711-6. doi: 10.7727/wimj.2014.012. Epub 2015 Mar 5.
5
National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.美国食品和药物管理局批准羟基脲后 1998-2008 年镰状细胞病住院治疗的国家趋势。
Med Care. 2014 Jul;52(7):612-8. doi: 10.1097/MLR.0000000000000143.
6
The glomerulopathy of sickle cell disease.镰状细胞病的肾小球病。
Am J Hematol. 2014 Sep;89(9):907-14. doi: 10.1002/ajh.23762. Epub 2014 Jun 19.
7
An update on sickle cell nephropathy.镰状细胞肾病的最新进展。
Saudi J Kidney Dis Transpl. 2014 Mar;25(2):249-65. doi: 10.4103/1319-2442.128495.
8
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.羟基脲可降低镰状细胞病患者蛋白尿的发生率。
Nephrol Dial Transplant. 2014 Jun;29(6):1211-8. doi: 10.1093/ndt/gft295. Epub 2013 Sep 30.
9
Sickle cell disease related mortality in the United States (1999-2009).美国镰状细胞病相关死亡率(1999-2009 年)。
Pediatr Blood Cancer. 2013 Sep;60(9):1482-6. doi: 10.1002/pbc.24557. Epub 2013 Apr 23.
10
Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.羟基脲治疗可降低镰状细胞贫血患儿的肾小球高滤过。
Am J Hematol. 2013 Feb;88(2):116-9. doi: 10.1002/ajh.23365. Epub 2012 Dec 17.

镰状细胞病中的肾衰竭:患病率、疾病预测因素、死亡率及对住院时间的影响

Renal Failure in Sickle Cell Disease: Prevalence, Predictors of Disease, Mortality and Effect on Length of Hospital Stay.

作者信息

Yeruva Sri L H, Paul Yonette, Oneal Patricia, Nouraie Mehdi

机构信息

a Department of Internal Medicine, Division of Hematology/Oncology , Howard University Hospital , Washington , DC , USA.

b Department of Medicine and Vascular Medicine Institute , University of Pittsburgh , Pittsburgh , PA , USA.

出版信息

Hemoglobin. 2016 Sep;40(5):295-299. doi: 10.1080/03630269.2016.1224766. Epub 2016 Sep 18.

DOI:10.1080/03630269.2016.1224766
PMID:27643740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5207341/
Abstract

Renal dysfunction in sickle cell disease is not only a chronic comorbidity but also a mortality risk factor. Though renal dysfunction starts early in life in sickle cell patients, the predictors that can identify sickle cell disease patients at risk of developing renal dysfunction is not known. We used the Truven Health MarketScan Medicaid Databases from 2007 to 2012. Incidence of new acute renal failure (ARF) and chronic kidney disease (CKD) was calculated in this cohort. There were 9481 patients with a diagnosis of sickle cell disease accounting for 64,201 hospital admissions, during the study period. Both ARF and CKD were associated with higher risk of inpatient mortality, longer duration of the hospital stay and expensive hospitalizations. The yearly incidence of new ARF in sickle cell disease patients was 1.4% and annual CKD incidence was 1.3%. The annual rate of new ARF and CKD in the control group was 0.4 and 0.6%, respectively. The most important predictors of new CKD were proteinuria, ARF and hypertension. Chronic kidney disease, hypertension and sickle cell crisis were the most important predictors of new ARF. The annual rate of incidences of ARF and CKD were 2- to 3-fold higher in sickle cell disease compared to the non sickle cell disease group. Besides the common risk factors for renal disease in the general population, it is imperative to monitor the sickle cell disease patients with more severe disease to prevent them from developing renal dysfunction.

摘要

镰状细胞病中的肾功能不全不仅是一种慢性合并症,也是一个死亡风险因素。尽管镰状细胞病患者在生命早期就开始出现肾功能不全,但尚不清楚哪些预测因素能够识别有发生肾功能不全风险的镰状细胞病患者。我们使用了2007年至2012年的Truven Health MarketScan医疗补助数据库。在该队列中计算了新发性急性肾衰竭(ARF)和慢性肾脏病(CKD)的发病率。在研究期间,有9481例诊断为镰状细胞病的患者,共计64201次住院。ARF和CKD均与住院死亡率较高、住院时间较长以及住院费用昂贵相关。镰状细胞病患者中新发性ARF的年发病率为1.4%,CKD的年发病率为1.3%。对照组中新发性ARF和CKD的年发病率分别为0.4%和0.6%。新发性CKD的最重要预测因素是蛋白尿、ARF和高血压。慢性肾脏病、高血压和镰状细胞危象是新发性ARF的最重要预测因素。与非镰状细胞病组相比,镰状细胞病中ARF和CKD的年发病率高出2至3倍。除了一般人群中常见的肾脏疾病风险因素外,对病情更严重的镰状细胞病患者进行监测以防止他们发生肾功能不全至关重要。